Strong synergy of heat and modulated electromagnetic field in tumor cell killing
/in Hyperthermia, International Publications /von 2009-02-25 / Strahlenther Onkol 2009 Feb;185(2):120-6Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response
/in Acute Leukemia, International Publications /von 2009-02-19 / Cancer Immunol. Immunother. 2009 Oct;58(10):1669-77Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses
/in Hypernephroma, International Publications /von 2009-02-17 / Cancer Immunol. Immunother. 2009 Oct;58(10):1587-97Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice
/in Colorectal Cancer, International Publications /von 2009-02-15 / Int. J. Cancer 2009 Feb;124(4):877-88Dendritic-cell- and peptide-based vaccination strategies for glioma
/in Glioblastoma, International Publications /von 2009-02-13 / Neurosurg Rev 2009 Jul;32(3):265-73; discussion 273Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses
/in International Publications, Newcastle Disease Virus /von 2009-02-10 / Mol. Ther. 2009 Apr;17(4):697-706FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer
/in International Publications, Prostate Cancer /von 2009-02-08 / Clin. Immunol. 2009 Apr;131(1):1-10Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer
/in Dendritic Cells, International Publications /von 2009-02-05 / Vaccine 2009 May;27(25-26):3401-4Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2009-02-03 / Cancer Res. 2009 Feb;69(4):1448-58
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution